Seventeen years later, as the top drug regulator in the United States, H\u00f8eg faces accusations from staff at the Food and Drug Administration of doing the very same thing.\u00a0<\/p>\n
On Monday, H\u00f8eg will become acting director of the FDA\u2019s Center for Drug Evaluation and Research<\/a>. It\u2019s a role where dispassionately reviewing complicated scientific evidence about the benefits and harms of medical treatments is paramount. H\u00f8eg, her bosses, and former colleagues say she is up to the task. But in her nine months as scientific adviser to FDA Commissioner Marty Makary, H\u00f8eg\u2019s track record has raised questions about her ability to oversee drug regulation without bias.<\/p>\n STAT+ Exclusive Story<\/p>\n Already have an account? Log in<\/a><\/p>\n \t\t\t \t\t\t\t\t \t\t\t\tThis article is exclusive to STAT+ subscribers Already have an account? Log in<\/a><\/p>\n \t\t\t\t\t\tIndividual plans<\/p>\n \t\t\t\t\t\tGroup plans<\/p>\n![\"STAT+\"\/](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/12\/1765280600_844_stat-plus-breaker-bg.png\")
<\/p>\n
\n\t\t\t\t\t\t![\"STAT+\"\/](\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\"){kind=logo}
\n\t\t\t\t\t<\/a><\/p>\n
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n